[Dementia in Patients with Central Nervous System Mycosis]

Area of Science:

• Neurology
• Infectious Diseases
• Mycology

Background:

• Central nervous system (CNS) mycosis presents as a treatable neurological emergency, often mimicking dementia.
• While frequently associated with underlying conditions like HIV, cancer, or immunosuppression, cryptococcosis can affect non-immunosuppressed individuals.
• Accurate diagnosis is hindered by the difficulty in detecting fungal pathogens in cerebrospinal fluid (CSF) cultures.

Observation:

• Clinical diagnosis often relies on a combination of CSF analysis (pleocytosis, low glucose, elevated protein), antigen assays, and (1-3)-beta-D-glucan tests.
• Magnetic resonance imaging (MRI) aids in evaluating complications such as abscesses, infarction, and hydrocephalus.
• Polymerase chain reaction (PCR)-based diagnostics offer sensitive, albeit not routine, tools for early CNS mycosis detection in research settings.

Findings:

• Despite diagnostic challenges, a multi-faceted approach combining clinical, laboratory, and imaging data is essential.
• PCR diagnostics show promise for earlier identification of CNS fungal infections.
• Understanding the strengths and limitations of each diagnostic modality is key for clinicians.

Implications:

• Timely and precise diagnosis, including fungal species identification, is paramount for initiating appropriate antifungal therapy.
• Prompt treatment based on accurate diagnosis significantly improves patient prognosis for CNS mycosis.
• Further integration of advanced diagnostics like PCR could enhance early detection and management strategies.